Market World United States Diphtheria Vaccine Market Scope | Page 2

advanced vaccines, and concerns about health issues. The other factors include rising prevalence of
chronic disease and increasing usage of therapy and vaccine. However, side effects, lack of accuracy,
complications during inhalation, and high prices of devices are likely to negatively impact the
growth of industry.
United States diphtheria vaccine industry is categorized based on product, vaccine type, age group,
end user, and geography. Based on product, the United States diphtheria vaccine market is
classified as DT, DTaP, Td, and Tdap. The segment “DTaP” is sub-divided into Infanrix, Daptacel,
Pediarix, Kinrix, Pentacel and Quaracel. Also, the segment “Tdap” is sub-divided by Adacel and
Boostrix. Similarly, “Td” segment is sub-divided by Tenivac and Decavac.
Request Sample Copy of this Market Research @
https://www.millioninsights.com/industry-reports/united-states-diphtheria-vaccine-market/request-sample
Based on vaccine type, the United States diphtheria vaccine industry is classified as a cellular
vaccine and whole-cell vaccine. Based on age group, the market is classified as for infants & children
younger than seven years of age and for adolescents & adults. Based on end user, the industry is
classified as clinics, hospitals, and vaccination centers. Based on geography, the market spans
Southwest, The Middle Atlantic, The West, New England, The South, and The Midwest.
Key players operating in the United States diphtheria vaccine market include Sanofi Pasteur,
GlaxoSmithKline, Merck, Wyeth (Pfizer), Changchun Changsheng Life Sciences, Novartis, Shanghai
Institute of Biological Products, Beijing Tiantan Biological Products, Wuhan Institute of Biological
Products, and Chengdu Institute of Biological Products.
Market Segment:
Geographically, this report splits the United States market into seven regions:
• The West
• Southwest
• The Middle Atlantic
• New England
• The South
• The Midwest